S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.87 (-2.83%)
AAPL   141.91 (-2.38%)
MSFT   283.52 (-3.62%)
FB   340.65 (-3.66%)
GOOGL   2,716.60 (-3.72%)
TSLA   777.56 (-1.74%)
AMZN   3,315.96 (-2.64%)
NVDA   206.99 (-4.44%)
BABA   152.39 (+1.47%)
NIO   35.05 (-4.68%)
CGC   14.21 (-3.40%)
GE   105.73 (+0.36%)
MU   73.10 (-2.77%)
AMD   101.52 (-6.14%)
T   27.24 (-0.58%)
F   14.31 (+1.06%)
ACB   6.81 (+6.57%)
DIS   174.52 (-2.10%)
PFE   43.04 (-1.22%)
BA   218.41 (-2.57%)
AMC   36.99 (-5.88%)
S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.87 (-2.83%)
AAPL   141.91 (-2.38%)
MSFT   283.52 (-3.62%)
FB   340.65 (-3.66%)
GOOGL   2,716.60 (-3.72%)
TSLA   777.56 (-1.74%)
AMZN   3,315.96 (-2.64%)
NVDA   206.99 (-4.44%)
BABA   152.39 (+1.47%)
NIO   35.05 (-4.68%)
CGC   14.21 (-3.40%)
GE   105.73 (+0.36%)
MU   73.10 (-2.77%)
AMD   101.52 (-6.14%)
T   27.24 (-0.58%)
F   14.31 (+1.06%)
ACB   6.81 (+6.57%)
DIS   174.52 (-2.10%)
PFE   43.04 (-1.22%)
BA   218.41 (-2.57%)
AMC   36.99 (-5.88%)
S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.87 (-2.83%)
AAPL   141.91 (-2.38%)
MSFT   283.52 (-3.62%)
FB   340.65 (-3.66%)
GOOGL   2,716.60 (-3.72%)
TSLA   777.56 (-1.74%)
AMZN   3,315.96 (-2.64%)
NVDA   206.99 (-4.44%)
BABA   152.39 (+1.47%)
NIO   35.05 (-4.68%)
CGC   14.21 (-3.40%)
GE   105.73 (+0.36%)
MU   73.10 (-2.77%)
AMD   101.52 (-6.14%)
T   27.24 (-0.58%)
F   14.31 (+1.06%)
ACB   6.81 (+6.57%)
DIS   174.52 (-2.10%)
PFE   43.04 (-1.22%)
BA   218.41 (-2.57%)
AMC   36.99 (-5.88%)
S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.87 (-2.83%)
AAPL   141.91 (-2.38%)
MSFT   283.52 (-3.62%)
FB   340.65 (-3.66%)
GOOGL   2,716.60 (-3.72%)
TSLA   777.56 (-1.74%)
AMZN   3,315.96 (-2.64%)
NVDA   206.99 (-4.44%)
BABA   152.39 (+1.47%)
NIO   35.05 (-4.68%)
CGC   14.21 (-3.40%)
GE   105.73 (+0.36%)
MU   73.10 (-2.77%)
AMD   101.52 (-6.14%)
T   27.24 (-0.58%)
F   14.31 (+1.06%)
ACB   6.81 (+6.57%)
DIS   174.52 (-2.10%)
PFE   43.04 (-1.22%)
BA   218.41 (-2.57%)
AMC   36.99 (-5.88%)
NASDAQ:EXPO

Exponent Stock Forecast, Price & News

$115.09
-3.68 (-3.10 %)
(As of 09/28/2021 12:00 AM ET)
Add
Compare
Today's Range
$114.99
$118.68
50-Day Range
$92.70
$119.55
52-Week Range
$68.42
$120.39
Volume183,626 shs
Average Volume193,363 shs
Market Capitalization$5.99 billion
P/E Ratio63.59
Dividend Yield0.67%
Beta0.36
30 days | 90 days | 365 days | Advanced Chart
Receive EXPO News and Ratings via Email

Sign-up to receive the latest news and ratings for Exponent and its competitors with MarketBeat's FREE daily newsletter.


Exponent logo

About Exponent

Exponent, Inc. is an engineering and scientific consulting company, which engages in the provision of engineering, scientific, environmental, and health consulting services. It operates through the following segments: Engineering and Other Scientific and Environmental and Health. The Engineering and Other Scientific segment include technical consulting in different practices primarily in engineering. The Environmental and Health segment offers services in the area of environmental, epidemiology, and health risk analysis. The company was founded by Bernard Ross in 1967 and is headquartered in Menlo Park, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Management consulting services
Sub-Industry
Research & Consulting Services
Current Symbol
NASDAQ:EXPO
CUSIP
30214U10
Employees
1,168
Year Founded
1967

Sales & Book Value

Annual Sales
$399.90 million
Cash Flow
$1.73 per share
Book Value
$7.00 per share

Profitability

Net Income
$82.55 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$5.99 billion
Next Earnings Date
11/4/2021 (Estimated)
Optionable
Optionable

Social Links


MarketRank

Overall MarketRank

2.20 out of 5 stars

Business Services Sector

95th out of 392 stocks

Management Consulting Services Industry

9th out of 26 stocks

Analyst Opinion: 1.3Community Rank: 4.3Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -












Exponent (NASDAQ:EXPO) Frequently Asked Questions

Is Exponent a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exponent in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Exponent stock.
View analyst ratings for Exponent
or view top-rated stocks.

What stocks does MarketBeat like better than Exponent?

Wall Street analysts have given Exponent a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Exponent wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Exponent?

Exponent saw a decrease in short interest in August. As of August 13th, there was short interest totaling 870,700 shares, a decrease of 14.6% from the July 29th total of 1,020,000 shares. Based on an average trading volume of 186,800 shares, the days-to-cover ratio is currently 4.7 days. Approximately 1.7% of the company's shares are short sold.
View Exponent's Short Interest
.

When is Exponent's next earnings date?

Exponent is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Exponent
.

How were Exponent's earnings last quarter?

Exponent, Inc. (NASDAQ:EXPO) issued its quarterly earnings data on Thursday, July, 29th. The business services provider reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.06. The business services provider earned $112.47 million during the quarter, compared to analyst estimates of $106.11 million. Exponent had a trailing twelve-month return on equity of 26.17% and a net margin of 21.94%.
View Exponent's earnings history
.

How has Exponent's stock been impacted by COVID-19?

Exponent's stock was trading at $75.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EXPO shares have increased by 51.5% and is now trading at $115.09.
View which stocks have been most impacted by COVID-19
.

How often does Exponent pay dividends? What is the dividend yield for Exponent?

Exponent announced a quarterly dividend on Thursday, July 29th. Shareholders of record on Friday, September 10th will be given a dividend of $0.20 per share on Friday, September 24th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.70%. The ex-dividend date is Thursday, September 9th.
View Exponent's dividend history
.

Is Exponent a good dividend stock?

Exponent pays an annual dividend of $0.80 per share and currently has a dividend yield of 0.67%. Exponent does not yet have a strong track record of dividend growth. The dividend payout ratio of Exponent is 51.61%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Exponent will have a dividend payout ratio of 41.67% next year. This indicates that Exponent will be able to sustain or increase its dividend.
View Exponent's dividend history.

When did Exponent's stock split? How did Exponent's stock split work?

Exponent's stock split before market open on Thursday, June 7th 2018. The 2-1 split was announced on Tuesday, May 15th 2018. The newly issued shares were payable to shareholders after the closing bell on Wednesday, June 6th 2018. An investor that had 100 shares of Exponent stock prior to the split would have 200 shares after the split.

What price target have analysts set for EXPO?

3 brokerages have issued 12 month price targets for Exponent's stock. Their forecasts range from $118.00 to $118.00. On average, they expect Exponent's share price to reach $118.00 in the next twelve months. This suggests a possible upside of 2.5% from the stock's current price.
View analysts' price targets for Exponent
or view top-rated stocks among Wall Street analysts.

Who are Exponent's key executives?

Exponent's management team includes the following people:
  • Catherine Ford Corrigan, President, Chief Executive Officer & Director
  • Richard L. Schlenker, Chief Financial Officer, Secretary & Executive VP
  • Subbaiah V. Malladi, Chief Technical Officer
  • Suresh H. Moolgavkar, Vice President
  • Eric R. Anderson, Vice President & Controller

What is Catherine Corrigan's approval rating as Exponent's CEO?

15 employees have rated Exponent CEO Catherine Corrigan on Glassdoor.com. Catherine Corrigan has an approval rating of 84% among Exponent's employees.

What other stocks do shareholders of Exponent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exponent investors own include AbbVie (ABBV), Pfizer (PFE), Abbott Laboratories (ABT), Energy Transfer (ET), Ford Motor (F), Micron Technology (MU), AT&T (T), UnitedHealth Group (UNH), Visa (V) and Adobe (ADBE).

What is Exponent's stock symbol?

Exponent trades on the NASDAQ under the ticker symbol "EXPO."

Who are Exponent's major shareholders?

Exponent's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.00%), Vanguard Group Inc. (10.80%), Neuberger Berman Group LLC (6.23%), Kayne Anderson Rudnick Investment Management LLC (4.37%), Conestoga Capital Advisors LLC (3.83%) and State Street Corp (3.10%). Company insiders that own Exponent stock include Bradley A James, Carol Lindstrom, Harri Kytomaa, John Pye, Maureen T F Reitman, Paul R Johnston, Paul R Johnston, Richard L Schlenker Jr, Richard Reiss, Sally Shepard and Steven J Murray.
View institutional ownership trends for Exponent
.

Which institutional investors are selling Exponent stock?

EXPO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, AXA S.A., Neuberger Berman Group LLC, Deutsche Bank AG, Canada Pension Plan Investment Board, JPMorgan Chase & Co., and Copeland Capital Management LLC. Company insiders that have sold Exponent company stock in the last year include Bradley A James, Carol Lindstrom, Harri Kytomaa, John Pye, Maureen T F Reitman, Paul R Johnston, Richard L Schlenker Jr, and Steven J Murray.
View insider buying and selling activity for Exponent
or view top insider-selling stocks.

Which institutional investors are buying Exponent stock?

EXPO stock was bought by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, Millennium Management LLC, Renaissance Technologies LLC, Ardevora Asset Management LLP, Bank of Montreal Can, The Manufacturers Life Insurance Company , State Street Corp, and Vanguard Group Inc..
View insider buying and selling activity for Exponent
or or view top insider-buying stocks.

How do I buy shares of Exponent?

Shares of EXPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exponent's stock price today?

One share of EXPO stock can currently be purchased for approximately $115.09.

How much money does Exponent make?

Exponent has a market capitalization of $5.99 billion and generates $399.90 million in revenue each year. The business services provider earns $82.55 million in net income (profit) each year or $1.55 on an earnings per share basis.

How many employees does Exponent have?

Exponent employs 1,168 workers across the globe.

Does Exponent have any subsidiaries?

The following companies are subsidiares of Exponent: Dennis Publishing.

When was Exponent founded?

Exponent was founded in 1967.

What is Exponent's official website?

The official website for Exponent is www.exponent.com.

Where are Exponent's headquarters?

Exponent is headquartered at 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025.

How can I contact Exponent?

Exponent's mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The business services provider can be reached via phone at (650) 326-9400 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.